Search research articles
Contact Us
Filters
Showing results (261-270 of 292) with videos related to
Page
of 30
Sort By:
Breast Cancer Research and Treatment
|
October 15, 2013
Distinct nuclear receptor expression in stroma adjacent to breast tumors
Kevin C Knower, Ashwini L Chand, Natalie Eriksson, et al.
Developmental Cell
|
December 8, 2018
Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence
Nai Yang Fu, Bhupinder Pal, Yunshun Chen, et al.
Nature Communications
|
March 23, 2025
MCL‑1 safeguards activated hair follicle stem cells to enable adult hair regeneration
Hui San Chin, Jinming Cheng, Shih Han Hsu, et al.
Blood Advances
|
December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
Charis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
The EMBO Journal
|
April 11, 2025
Fibroblast hierarchy dynamics during mammary gland morphogenesis and tumorigenesis
Rosa Pascual, Jinming Cheng, Amelia H De Smet, et al.
Nature Medicine
|
August 4, 2009
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
Elgene Lim, François Vaillant, Di Wu, et al.
International Journal of Cancer
|
August 14, 2009
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status
Niamh C Murphy, Andrew V Biankin, Ewan K A Millar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2020
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer
James R Whittle, François Vaillant, Elliot Surgenor, et al.
Nature Cell Biology
|
January 12, 2024
Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers
Rachel Joyce, Rosa Pascual, Luuk Heitink, et al.
Science Translational Medicine
|
August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Delphine Merino, James R Whittle, François Vaillant, et al.
Page
of 30
Search research articles
Search
Showing results (261-270 of 292) with videos related to
Sort By:
Page
of 30
Breast Cancer Research and Treatment
|
October 15, 2013
Distinct nuclear receptor expression in stroma adjacent to breast tumors
Kevin C Knower, Ashwini L Chand, Natalie Eriksson, et al.
Developmental Cell
|
December 8, 2018
Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence
Nai Yang Fu, Bhupinder Pal, Yunshun Chen, et al.
Nature Communications
|
March 23, 2025
MCL‑1 safeguards activated hair follicle stem cells to enable adult hair regeneration
Hui San Chin, Jinming Cheng, Shih Han Hsu, et al.
Blood Advances
|
December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
Charis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
The EMBO Journal
|
April 11, 2025
Fibroblast hierarchy dynamics during mammary gland morphogenesis and tumorigenesis
Rosa Pascual, Jinming Cheng, Amelia H De Smet, et al.
Nature Medicine
|
August 4, 2009
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
Elgene Lim, François Vaillant, Di Wu, et al.
International Journal of Cancer
|
August 14, 2009
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status
Niamh C Murphy, Andrew V Biankin, Ewan K A Millar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2020
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer
James R Whittle, François Vaillant, Elliot Surgenor, et al.
Nature Cell Biology
|
January 12, 2024
Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers
Rachel Joyce, Rosa Pascual, Luuk Heitink, et al.
Science Translational Medicine
|
August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Delphine Merino, James R Whittle, François Vaillant, et al.
Page
of 30